Departed
Meg G. Crofton
Director
HCA ·
HCA Healthcare, Inc.
Retirement of Meg G. Crofton from the
Ready 8-Ks
25
Latest filing
April 30, 2026, 7:59 PM ET
Top materiality
0.85
Event mix
debt ×10 · earnings ×9 · other_material ×3
Sentiment
9 pos · 0 neg · 16 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for HCA
Highest-materiality recent filing
HCA Healthcare Q4 EPS $8.14 (up 44.6%), revenue $19.5B, $10B buyback authorized
- Q4 revenue $19.513B (+6.7% YoY); net income $1.878B (+30.6%); adjusted EBITDA $4.114B (+10.8%).
- Diluted EPS $8.14 (+44.6%), adjusted EPS $8.01 (+28.8%); same-facility admissions +2.4%, equivalent admissions +2.5%.
-
HCA Inc. issues $3B in senior notes across three tranches maturing 2031-2036
Issued $1B of 4.700% notes due 2031, $750M of 5.000% notes due 2033, and $1.25B of 5.300% notes due 2036.
-
All nine director nominees elected; votes for ranged from 173.1M (DeParle) to 193.7M (Hazen) shares.
-
HCA Inc. proposes senior notes offering; to redeem $2.5B in near-term notes
HCA Inc. proposes public offering of senior notes; terms not yet set.
-
HCA Q1 revenue up 4.3% to $19.1B; EPS rises 10.9% to $7.15; declares $0.78 dividend
Revenues $19.109B, net income $1.620B (+0.6% YoY); diluted EPS $7.15 (+10.9% YoY).
-
HCA sets 2026 exec comp: CEO target 175% of salary; board member Dennis to retire
CEO Samuel Hazen target award 175% of base; CFO/COO 125%; other named execs 100%.
-
HCA Healthcare Q4 EPS $8.14 (up 44.6%), revenue $19.5B, $10B buyback authorized
Q4 revenue $19.513B (+6.7% YoY); net income $1.878B (+30.6%); adjusted EBITDA $4.114B (+10.8%).
-
HCA issues $3.25B senior notes: 4.30% 2030, 4.60% 2032, 4.90% 2035, 5.70% 2055
$500M 4.30% notes due 2030, $1B 4.60% due 2032, $1B 4.90% due 2035, $750M 5.70% due 2055.
-
HCA subsidiary proposes senior notes offering, plans to redeem $1.5B 5.875% notes due 2026
HCA Inc. proposes public offering of senior unsecured notes; terms (maturity, rate, amount) to be set at pricing.
-
HCA Healthcare Q3 EPS $6.96, revenue $19.2B, raises 2025 guidance
Diluted EPS $6.96 (up 42.6% YoY); net income $1.643B (up 29.4%).
-
HCA Q2 revenue $18.6B (+6.4%), EPS $6.83 (+23.5%); raises 2025 guidance
Revenue $18.605B (+6.4% YoY); net income $1.653B (+13.1% YoY).
-
HCA Healthcare appoints John W. Chidsey, III as independent director, effective July 15
Board expands from 9 to 10 directors; Chidsey will serve on Audit & Compliance, Compensation, and Patient Safety & Quality of Care committees.
-
HCA Inc. establishes $4B commercial paper program, guaranteed by HCA Healthcare
Issuer HCA Inc. can issue up to $4B in unsecured commercial paper notes with maturities up to 397 days.
-
HCA stockholders OK 13.15M share increase for equity plan; officer exculpation amendment passed
Stockholders approved First Amendment to 2020 Stock Incentive Plan, adding 13,150,000 shares (total reserve now 18,542,144).
-
HCA Healthcare Q1 revenue $18.3B, EPS $6.45, adjusted EBITDA $3.73B, reaffirms guidance
Revenue $18.321B (+5.7% YoY); net income $1.610B, diluted EPS $6.45 (vs $5.93 prior year).
-
HCA director Crofton to retire at April 2025 annual meeting; exec incentive program adopted
Meg G. Crofton to retire from HCA board effective April 24, 2025 annual meeting.
-
HCA Inc. issues $5.25B of senior notes across six tranches maturing 2028-2055
Total $5.25B: $700M 5.000% notes due 2028, $300M floating-rate notes due 2028, $750M 5.250% due 2030.
-
HCA enters $8.0B unsecured revolver, terminates secured credit facilities
New $8.0B senior unsecured revolving credit facility with 5-year maturity dated Feb 20, 2025.
-
HCA subsidiary HCA Inc. proposes offering of senior notes; final terms (maturity, rate, amount) depend on market conditions.
-
HCA Q4 revenue $18.3B, EPS $5.63; 2025 EPS guidance $24.05-$25.85; $10B buyback authorized
Q4 revenue $18.285B (+5.7% YoY); net income $1.438B ($5.63 diluted EPS) vs $1.607B ($5.93) in 4Q23; includes $0.60/sh hurricane impact.
-
Revenue $17.487B (up 7.9% YoY), net income $1.270B (up 17.7%), diluted EPS $4.88 vs $3.91.
-
HCA Healthcare issues $3B in senior notes across three tranches with rates 5.45%-5.95%
$3B total: $750M 5.45% notes due 2031 (now $1.75B total), $1.25B 5.45% notes due 2034, $1B 5.95% notes due 2054.
-
HCA Healthcare issues $3B senior notes in three tranches; 2031 notes fungible with existing
$750M of 5.450% Senior Notes due 2031, issued as additional notes under existing indenture and fungible with prior $1B issue.
-
HCA Q2 2024 rev $17.49B, EPS $5.53, raises FY guidance
Revenue $17.492B (+10.3% YoY); net income $1.461B ($5.53 diluted EPS) vs $1.193B ($4.29).
-
William B. Rutherford retires as EVP/CFO effective May 1, 2024; Christopher Wyatt succeeds as principal accounting officer.
-
HCA Q1 revenue up 11% to $17.34B, EPS $5.93; reaffirms FY guidance
Revenue $17.339B (+11.2% YoY); net income $1.591B ($5.93 diluted EPS) vs $1.363B ($4.85).
Executive changes
Departed
William B. Rutherford
Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer
HCA ·
HCA Healthcare, Inc.
As previously announced, William B. Rutherford, HCA Healthcare, Inc.’s (the “Company’s”) Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer notified the Company of his intent to retire, effective May 1, 2024.
Appointed
Christopher F. Wyatt
Senior Vice President and Controller
HCA ·
HCA Healthcare, Inc.
In conjunction with Mr. Rutherford’s retirement, Christopher F. Wyatt, age 47, will succeed Mr. Rutherford as principal accounting officer, effective May 1, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event debt